Valeritas Shares Presentation of Its CBD H-Patch Data at Cannabinoid Summit

Valeritas is a renown medical technology company, known for its V-Go wearable insulin delivery device. This company presented its H-Patch data in Boston during the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit. This data showed that when 40mg of CBD is delivered for more than a day with the H–Patch technology, it's distributed and absorbed rapidly. This study also adds that using CBD causes effects after approximately one hour and that taking 40mg of CBD increased plasma levels in a human being.

John Timberlake, who is the Chief Executive Officer of this company, says that Valeritas is very contented with the results of their PK study. He adds that he is proud that his H-Patch technology can provide high plasma levels in the same way that oral administration does.

John says that what makes their CBD technology better is the fact that using only a fraction of it produces highly effective results. According to John, Valeritas is also looking forward to working with companies all over the world that can benefit from using the h-Patch technology.

“We are very excited by the data from this PK study and the potential our h-Patch™ technology has in providing peak plasma levels equivalent to oral administration despite delivering only a fraction of the amount of CBD,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We look forward to partnering with companies who could benefit from utilizing the h-Patch™ to deliver their therapeutics.”

Therefore, Valeritas is providing the best drug delivery technology hence facilitating a simple but effective way to deliver injectable medicines to patients with different therapeutic conditions.